Neurology

ACTRIMS 2025

Genetic and phenotypic risk model predicts MS

Presented By

Ms Alyks Linerud, Brigham Young University, UT, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:38

Novel AI algorithm better identifies risk factors of MS

Presented By

Dr Zongqi Xia, University of Pittsburgh, PA, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:36

Paramagnetic rim lesions predict effectiveness of tolebrutinib

Presented By

Dr Jiwon Oh, University of Toronto, Canada

Trial

HERCULES, GEMINI

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:34

Atypical and radiological-only presentations often meet 2024 MS criteria

Presented By

Ms Alexandra Scharf, Cleveland Clinic, OH, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:29

Treatment with cladribine tablets: real-world insights

Presented By

Mr Gerard Harty, Merck KGaA, Germany

Trial

CLADRISE

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:27

Favourable effectiveness and persistence of cladribine versus other oral DMTs

Presented By

Prof. Helmut Butzkueven, Monash University, Australia

Trial

GLIMPSE

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:26

Ofatumumab: good initial adherence and treatment satisfaction

Presented By

Dr Anneke van der Walt, Monash University, Australia

Trial

EAFToS

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:24

MS activity remains low on long-term fenebrutinib

Presented By

Prof. Amit Bar-Or, University of Pennsylvania, PA, USA

Trial

Phase 2, FENopta

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:22

Higher-dosed ocrelizumab associated with less disability accrual

Presented By

Dr Robert Bermel, Cleveland Clinic, OH, USA

Trial

Phase 3, OPERA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:21

Ocrelizumab significantly reduces new/enlarging cortical lesions

Presented By

Prof. Michael Dwyer, University at Buffalo, NY, USA

Trial

Phase 3, ORATORIO

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:19

Discontinuing therapy has few risks in patients with MS over 60 years

Presented By

Prof. John Corboy, University of Colorado, CO, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:17

Comorbidity burden associated with risk of adverse events

Presented By

Prof. Amber Salter, UT Southwestern Medical Center, TX, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:15

Update on safety profile of cladribine tablets yields positive results

Presented By

Prof. Thomas Leist, Jefferson University, PA, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:14

Safety of 30-minute ublituximab infusions confirmed

Presented By

Dr John Foley, Rocky Mountain Multiple Sclerosis Center, UT, USA

Trial

ENHANCE

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:12

Meningococcal vaccination prior to ravulizumab use seems effective

Presented By

Dr Michael Levy, Harvard Medical School, MA, USA

Trial

Phase 3, CHAMPION-NMOSD

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:10

Orelabrutinib highly effective in relapsing-remitting MS, based on MRI results

Presented By

Prof. Yan Xu, Peking Union Medical College Hospital, China

Trial

Phase 2

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:08

Immunomodulatory potential of ketogenic diet in MS confirmed

Presented By

Dr Michael Kornberg, Johns Hopkins University, MD, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:06

A pre-relapse immune signature implicates EBV reactivation in MS relapse

Presented By

Dr Devin King, Brigham and Women’s Hospital, MA, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:03

Meet the Trialist: Dr Jiwon Oh

Expert

Dr Jiwon Oh, St Michael’s Hospital, University of Toronto, Canada

Conference

ACTRIMS 2025

5 March 2025 10:59

EHC 2024

ECTRIMS 2024

Introduction to the ECTRIMS 2024 Conference Report

Presented By

Dr Rachel Giles, Medicom

Conference

ECTRIMS 2024

25 November 2024 10:08

Editor Biography

Editor

Prof. Hans-Peter Hartung, Heinrich-Heine-University Düsseldorf, Germany

Conference

ECTRIMS 2024

25 November 2024 10:05

Revised McDonald criteria allow earlier and more precise MS diagnosis

Presented By

Prof. Xavier Montalban, Vall d'Hebron University Hospital, Spain

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:52

Approaches to RIS and MS converge

Presented By

Prof. Christine Lebrun-Frénay, Centre Hospitalier Universitaire de Nice, France

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:50

AI versus clinicians: who diagnoses MS faster and better?

Presented By

Ms Mahi Patel, UT Southwestern, TX, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:47

Blood markers predict MS progression

Presented By

Dr Ahmed Abdelhak, University of California San Francisco, CA, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:46

Gut microbiota modulate inflammation and cortical damage

Presented By

Dr Federico Montini, Brigham and Women's Hospital, MA, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:43

Risk factors and importance of persistent PIRA

Presented By

Dr Chao Zhu, Monash University, Australia

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:39

Vitamin D supplementation in progressive MS should be medically supervised

Presented By

Dr Michaela Haindl, Medical University of Graz, Austria

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:38

Encouraging real-world results of AHSCT to treat aggressive MS

Presented By

Prof. Paolo Muraro, London Bridge Hospital, UK

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:35

CAR T-cell therapy in MS: in its infancy but highly anticipated

Presented By

Prof. Frauke Zipp, Johannes Gutenberg University Mainz, Germany

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:33

B cell-tailored dosing of ocrelizumab shows good results

Presented By

Ms Laura Hogenboom, Amsterdam University Medical Center, the Netherlands

Trial

BLOOMS

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:28

Risk associated with discontinuing therapy depends on specific drug

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:26

First-line moderate-efficacy DMTs show similar efficacy

Presented By

Dr Clara López-Caneda, Hospital Alvaro Cunqueiro, Spain

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:23

Tolebrutinib slows disability worsening in relapsing MS

Presented By

Dr Jiwon Oh, St. Michael's Hospital, Canada

Trial

Phase 3, GEMINI 1, GEMINI 2

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:21

Frexalimab shows favourable safety and efficacy in OLE

Presented By

Prof. Gavin Giovannoni, Queen Mary University of London, UK

Trial

Phase 2

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:17

Good safety of ozanimod over up to 8 years of treatment

Presented By

Prof. Krzysztof Selmaj, University of Warmia and Mazury, Poland

Trial

DAYBREAK

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:16

Tolebrutinib slows disability in non-relapsing SPMS

Presented By

Prof. Robert Fox, Cleveland Clinic, OH, USA

Trial

Phase 3, HERCULES

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:13

High-dose simvastatin does not slow disability progression in SPMS

Presented By

Dr Jeremy Chataway, University College London, UK

Trial

Phase 3, MS-STAT2

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:11

High genetic burden for depression associated with MS disease activity

Presented By

Dr Kaarina Kowalec, University of Manitoba, Canada

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:06

More comorbidity is associated with worse clinical outcomes in MS

Presented By

Dr Amber Salter, UT Southwestern, TX, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:05

Transfer of ocrelizumab into breastmilk is negligible

Presented By

Dr Riley Bove, University of California San Francisco, CA, USA

Trial

Phase 4, SOPRANINO

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:03

Ineffective response to EBV in MS not seen in similar diseases

Presented By

Dr Tilman Schneider-Hohendorf, University of Münster, Germany

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:01

Comparative effectiveness and safety of DMTs in NMOSD

Presented By

Dr Philippe-Antoine Bilodeau, Brigham and Women’s Hospital, MA, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 11:59

Age, time, and treatment determine relapse risk in MOGAD

Presented By

Dr Vivien Häußler, University Medical Center Hamburg, Germany

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 11:56

ECTRIMS 2024 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

ECTRIMS 2024

8 October 2024 11:33

EAN 2024

MSMilan 2023

Retinal OCT markers hold promise for early MS diagnosis

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:13

Early intensive treatment enhances long-term clinical outcomes

Presented By

Dr Pietro Iaffaldano, University of Bari, Italy

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:12

χ-separation can assess the effects of tissue destruction in early MS lesions

Presented By

Dr Jannis Müller, University of Basel, Switzerland

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:12

Anti-CD40L antibody safe and effective in a phase 2 study

Trial

Phase 2

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:11

High sGFAP levels are associated with disease progression, independent of NfL or relapse activity

Presented By

Dr Pascal Benkert, University Hospital Basel, Switzerland

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:11

Oral glycolipid shows promise in the treatment of MS, especially SPMS

Presented By

Dr Tomoko Okamoto, National Center Hospital, Tokyo, Japan

Trial

Phase 2

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

Prioritising high efficacy therapies in children with MS

Presented By

Dr Nail Benallegue, Nantes University, France

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

New insights into the contribution of EBV to MS pathogenesis

Presented By

Prof. Thomas Berger, Medical University of Vienna, Austria

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

Early initiation of highly active treatment associated with a lower risk of SPMS

Presented By

Dr Christine Lebrun-Frenay, CHU de Nice, France

Trial

SPAM

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

Broad rim lesions correlate with a rapidly progressive MS phenotype

Presented By

Dr Jussi Lehto, University of Turku, Finland

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

Progressive brain tissue loss precedes the onset of clinical MS by years

Presented By

Dr Christina Azevedo, University of Southern California, CA, USA

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

COVID-19 infection associated with higher MS relapse rate

Presented By

Mr David Levitz, Monash University, Australia

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

An update on evolving treatment algorithms for NMOSD and MOGAD

Presented By

Prof. Jeffrey Bennett, University of Colorado, CO, USA

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Rate of grey matter brain atrophy accelerates after menopause

Presented By

Dr Alyssa Nylander, University of California, CA, USA

Trial

EPIC

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Omega-3 polyunsaturated fatty acids associated with lower risk of MS activity

Presented By

Dr Vinicius Schoeps, University of California, CA, USA

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Ocrelizumab more effective than interferon/glatiramer acetate in older MS patients

Presented By

Dr Yi Chao Foong, Monash University, Australia

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Smouldering inflammation detectable even in the earliest stages of MS

Presented By

Dr Markus Matilainen, University of Turku, Finland

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Fenebrutinib shows rapid reduction of new Gd+ T1 lesions

Presented By

Prof. Amit Bar-Or, University of Pennsylvania, PA, USA

Trial

Phase 2, FENopta

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Sickness absence rate increases years before clinical onset of MS

Presented By

Dr Ali Manouchehrinia, Karolinska University, Sweden

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Understanding what an MS cure means and what it takes

Presented By

Prof. Stephen Hauser, University of California, CA, USA

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Switching from rituximab to C5 complement inhibitors is safe in AQP4+ NMOSD

Trial

Phase 3, PREVENT, CHAMPION-NMOSD

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Letter from the Editor

Editor

Prof. Hans-Peter Hartung, Heinrich-Heine-University Düsseldorf, Germany

Conference

MSMilan 2023

4 December 2023 11:08

Telerehabilitation effective in improving MS symptoms in patients with moderate disability

Presented By

Dr Maria Petracca, Sapienza University of Rome, Italy

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Challenges of de-escalation versus discontinuation of highly effective DMTs in older MS patients

Presented By

Prof. Vincent Van Pesch, UCLouvain, Belgium

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Real-world data supports ocrelizumab prior to conception

Presented By

Dr Wei Yeh, Alfred Health and Monash University, Australia

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:07

MSMilan 2023 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ECTRIMS 2023

31 October 2023 12:14

EAN 2023

Letter from the Editor

Editor

Prof. Hans-Peter Hartung, Heinrich-Heine-University Düsseldorf, Germany

Conference

EAN 2023

7 September 2023 14:21

EAN guidelines on the management of ALS

Presented By

Prof. Philip van Damme, University Hospital Gasthuisberg, Belgium

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 12:12

What neurologists should know about bladder and sexual problems

Presented By

Prof. Jalesh Panicker, University College London, UK

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 12:08

Laughing gas abuse often leads to polyneuropathy, myelopathy, and encephalopathy

Presented By

Ms Anne Bruijnes, Maastricht University, the Netherlands

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 12:05

Nightmares during childhood linked to cognitive decline later in life

Presented By

Dr Abidemi Otaiku, University of Birmingham, UK

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:55

Sleep changes contribute to the pathogenesis of neurodegenerative diseases

Presented By

Dr Abubaker Ibrahim, Medical University of Innsbruck, Austria

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:51

Which patients can initially be treated with platform DMT?

Presented By

Dr Ilaria Addazio, University of Florence, Italy

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:44

Retinal layer thickness predicts disability accumulation in early RMS

Presented By

Prof. Gabriel Bsteh, Medical University of Vienna, Austria

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:38

Withdrawing DMF in early pregnancy does not increase relapse risk in pregnant patients with MS

Presented By

Prof. Doriana Landi, University of Rome Tor Vergata, Italy

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:12

Immunosenescence and MS: relevance to immunopathogenesis and treatment

Presented By

Prof. Monika Adamczyk-Sowa, Medical University of Silesia, Poland

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:04

GLP-1 agonists induce weight loss and alleviate headache in idiopathic intracranial hypertension

Presented By

Dr Nik Krajnc, Medical University of Vienna, Austria

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:00

Cannabis-based medicine does not beat placebo in central neuropathic pain

Presented By

Dr Julie Hansen, Aarhus University, Denmark

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:56

80% of patients reverse from chronic to episodic migraine on anti-CGRP antibodies

Presented By

Dr Gabriella Egeo, IRCCS San Raffaele, Italy

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:52

Minimising co-medication optimises cenobamate efficacy in drug-resistant epilepsy

Presented By

Dr Juan Sanchez-Caro, Advanced Neurology Center, Spain

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:42

Towards cell biology of Alzheimer’s disease

Presented By

Prof. Thomas C. Südhof, Stanford Medicine, CA, USA

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:35

New study characterises brain fog

Presented By

Dr Mohammad Mahmud, Imperial College London, UK

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:32

Intensive BP reduction associated with smaller haematoma

Presented By

Prof. Qi Li, Chongqing Medical University, China

Trial

Phase 3, ATACH-2

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:26

Amantadine in early COVID-19 enhances recovery

Presented By

Prof. Konrad Rejdak, Medical University of Lublin, Poland

Trial

Phase 3, COV-PREVENT

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:13

SARS-CoV-2 vaccination in CIDP and MMN: more benefit than harm

Presented By

Dr. Pietro Doneddu, IRCCS-Humanitas Reserach Institute, Italy

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:09

Contribution of genomics and genetics to personalised medicine

Presented By

Prof. Nicholas Wood, University College London, UK

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 09:56

How big data can boost care for neurodegenerative disorders

Presented By

Prof. Gunhild Waldemar, University of Copenhagen, Denmark

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 09:46

Alzheimer’s disease and dementia: the road towards proactive and preventive care

Expert

Dr John Showalter, Linus Health, Boston, MA, USA

21 August 2023 14:51

EAN 2023 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

EAN 2023

18 July 2023 12:18

AAN 2023

Artificial intelligence applications in neurology: seize the moment

Presented By

Prof. Kathryn Davis, Penn Medicine, PA, USA

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 21:10

Spinal cord stimulation eases painful diabetic neuropathy

Presented By

Dr Erika Petersen, University of Arkansas, AR, USA

Trial

SENZA-PDN

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 21:08

EVT improves functional outcomes in Chinese patients with BAO

Presented By

Prof. Raul Nogueira, Grady Memorial Hospital, GA, USA

Trial

ATTENTION

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 21:05

Severe sleep apnoea associated with white matter hyperintensities

Presented By

Dr Diego Carvalho, Mayo Clinic, MN, USA

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 21:03

Harnessing the microbiome as a possible stroke treatment

Presented By

Prof. Louise McCullough, University of Texas Health Science Center, TX, USA

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 21:00

Patients with a large core infarct benefit from thrombectomy

Presented By

Dr Amrou Sarraj, UH Cleveland Medical Center, OH, USA

Trial

Phase 3, SELECT2

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:57

Continuous levodopa/carbidopa infusion shows favourable safety and efficacy

Presented By

Dr Aaron Ellenbogen, Michigan Institute for Neurological Disorders, MI, USA

Trial

Phase 2, BeyoND

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:54

Unilateral right STN-DBS improves verbal fluency

Presented By

Dr Victor del Bene, University of Alabama, AL, USA

Trial

SUNDIAL

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:52

First-ever ALS platform trial reports on outcomes of 4 treatments

Presented By

Prof. Sabrina Paganoni, Massachusetts General Hospital, MA, USA

Trial

HEALEY ALS Platform Trial

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:49

Pridopidine for Huntington’s disease fails to meet the primary endpoint

Presented By

Prof. Andrew Feigin, NYU Grossman School of Medicine, NY, USA

Trial

Phase 3, PROOF-HD

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:46

Transcriptome data predicts long-term outcomes in untreated PPMS patients

Trial

ORATORIO

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:42

Teriflunomide prevents conversion to MS in patients with RIS

Presented By

Prof. Christine Lebrun-Frenay, Centre Hospitalier Universitaire de Nice, France

Trial

Phase 3, TERIS

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:39

Positive 4-year efficacy and safety data of ocrelizumab in early MS

Trial

Phase 3, ENSEMBLE

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:36

Gold nanocrystals may be effective as adjunctive MS therapy

Presented By

Prof. Michael Barnett, University of Sydney, Australia

Trial

Phase 2, VISIONARY-MS

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:33

Stem cell therapy fails primary endpoint but improves walking in more advanced progressive MS

Trial

Phase 2

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:30

Ravulizumab effective in AQP4+ NMOSD

Presented By

Dr Sean Pittock, Mayo Clinic, NY, USA

Trial

Phase 3, CHAMPION-NMOSD

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:28

Lecture on migraine: from the prodromal phase to future paradigm shifts

Presented By

Prof. Peter Goadsby, King's College London, UK

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:24

Zavegepant nasal spray exhibits good efficacy and safety in acute migraine

Presented By

Prof. Richard Lipton, Albert Einstein College of Medicine, NY, USA

Trial

Phase 3

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:18

Atogepant helps prevent treatment-resistant episodic migraine

Trial

ELEVATE

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:13

Simultaneous head-to-head comparison of 25 migraine medications

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:10

A vaccine as a potentially safe and effective immunotherapy against CGRP

Presented By

Dr Jean-Cosme Dodart, Vaxxinity Inc, FL, USA

Trial

Phase 1, UB-313

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:04

Seizure forecasting and detection with wearable devices are feasible

Presented By

Dr Benjamin Brinkmann, Mayo Clinic, MI, USA

Trial

My Seizure Gauge

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 19:56

Encouraging first results of GABAergic interneurons implants for focal epilepsy

Presented By

Prof. David Spencer, Oregon Health & Science University, OR, USA

Trial

Phase 1/2, NTRX-1001 GABAergic interneuron cell therapy

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 19:50

Lecanemab may slow decline of cognition and function in Alzheimer’s Disease

Presented By

Prof. Christopher van Dyck, Yale School of Medicine, CT, USA

Trial

Phase 3, CLARITY AD

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 19:44

Donanemab shows rapid and deep plaque clearance in early Alzheimer’s Disease

Presented By

Prof. Stephen Salloway, Warren Alpert Medical School of Brown University, RI, USA

Trial

Phase 3, TRAILBLAZER-ALZ 4

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 19:38

Original antigenic sin influences humoral immune response to SARS-CoV-2

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 19:36

Allogenic T-cell-based immunotherapy for PML in development

Presented By

Dr George Ambalathingal, QIMR Berghofer Medical Research Institute, Australia

Trial

Phase 2, CE-VST01-JC

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 19:32

Letter from the Editor

Editor

Prof. Hans-Peter Hartung , Heinrich Heine University, Düsseldorf, Germany

Conference

AAN 2023

26 June 2023 19:19

AAN 2023 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

AAN 2023

14 May 2023 19:44

Positive results for hereditary transthyretin-mediated amyloid polyneuropathy

Expert

Prof. Sami Khella, University of Pennsylvania, PA, USA

Trial

Phase 3, NEURO-TTRansform

Conference

AAN 2023

26 April 2023 14:01

EHC 2022

ECTRIMS 2022

Letter from the Editor

Editor

Prof. Hans-Peter Hartung, Heinrich-Heine-University Düsseldorf, Germany

Conference

ECTRIMS 2022

20 December 2022 12:12

Re-myelination strategies in MS still pose many unanswered questions

Presented By

Prof. Catherine Lubetzki, Sorbonne University, France

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 12:01

MS associated with a broader Epstein-Barr virus specific T-cell receptor repertoire

Presented By

Dr Tilman Schneider-Hohendorf, University of Muenster, Germany

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:58

Cognitive rehab and mindfulness reduce cognitive complaints in MS

Presented By

Dr Ilse Nauta, Vrije Universiteit Amsterdam, the Netherlands

Trial

REMIND-MS

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:56

COVID-19 and MS: lessons learned thus far

Presented By

Prof. Céline Louapre, Sorbonne University, France

Trial

COVISEP

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:52

Ocrelizumab and fingolimod increase the risk of COVID-19 and of worse outcomes

Presented By

Dr Nikos Evangelou, Nottingham University Hospital, UK

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:46

Humoral and cellular immune responses after SARS-CoV-2 vaccination

Presented By

Dr Monika Rabenstein, Karolinska Institute, Sweden

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:42

Ravulizumab significantly reduced relapses in AQP4+ NMOSD

Presented By

Dr Sean Pittock, Mayo Clinic, MN, USA

Trial

Phase 3, CHAMPION-NMOSD

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:36

NMOSD patients are cognitively impaired regardless of serostatus

Presented By

Dr Martin Hümmert, Hannover Medical School, Germany

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:25

Evidence-based consensus on pregnancy in NMOSD

Presented By

Prof. Sandra Vukusic, University Hospital Lyon, France

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 10:34

Pregnancy and infant outcomes in women receiving ocrelizumab

Presented By

Prof. Celia Oreja-Guevara, University Hospital San Carlos, Spain

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 10:29

New safety data of anti-CD20 mAbs around pregnancy

Presented By

Dr Carolin Schwake, Ruhr-University Bochum, Germany

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 10:24

MS activity and pregnancy outcomes after long-term use of natalizumab

Presented By

Prof. Sandra Thiel, Ruhr University Bochum, Germany

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 10:19

Early treatment with DMT effective in paediatric-onset MS

Presented By

Dr Emilio Portaccio, University of Florence, Italy

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:55

Fingolimod in paediatric MS: results of up to 6 years

Presented By

Dr Kumaran Deiva, Paris South University Hospitals, France

Trial

Phase 3, PARADIGMS

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:50

Switching treatment after initial platform injectable DMT: real-world data

Presented By

Dr Aaron Abrams, Cleveland clinic, OH, USA

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:43

Stem cell transplantation not superior to natalizumab in progressive MS

Presented By

Prof. Tomas Kalincik, Royal Melbourne Hospital, Australia

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:37

Efficacy of DMTs fades away in secondary progressive MS

Presented By

Dr Luigi Pontieri, The Danish Multiple Sclerosis Registry, Denmark

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:32

Smartphone tapping can help detect progressive MS

Presented By

Dr Juan Luis Chico-Garcia, Hospital Ramon y Cajal, Spain

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:19

Dimethyl fumarate reduces the risk of a first clinical event in RIS

Presented By

Prof. Darin Okuda, University of Texas Southwestern Medical Center, TX, USA

Trial

Phase 4, ARISE

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:14

How and when to make a timely switch to high-efficacy DMT

Presented By

Dr Dalia Rotstein, University of Toronto, Canada

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:08

Comparing real-world effectiveness of DMTs

Presented By

Prof. Marcello Moccia, University College London, UK

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:05

Study fails to show non-inferiority of rituximab to ocrelizumab

Presented By

Dr Izanne Roos, University of Melbourne, Australia

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 08:55

Autologous haematopoietic stem cell transplantation versus DMTs

Presented By

Prof. Tomas Kalincik, University of Melbourne, Australia

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 08:52

A case for including optic nerve lesions in the McDonald criteria

Presented By

Prof. Frederik Barkhof, Vrije Universiteit Amsterdam, the Netherlands

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 08:49

Cerebrospinal fluid kappa-free light chains for MS diagnosis

Presented By

Dr Harald Hegen, Medical University of Innsbruck, Austria

Conference

ECTRIMS 2022

Type

Peer-reviewed article

19 December 2022 19:19

Early, non-disabling relapses increase disability accumulation

Presented By

Dr Cyrus Daruwalla, Cambridge University Hospitals, UK

Conference

ECTRIMS 2022

Type

Peer-reviewed article

19 December 2022 19:13

Physical impairment is present before perceived MS onset

Presented By

Ms Annalaura Lerede, Imperial College London, UK

Conference

ECTRIMS 2022

Type

Peer-reviewed article

19 December 2022 19:09

Chronic active MS lesions respond poorly to anti-CD20 antibodies

Presented By

Dr Pietro Maggi, Saint-Luc University Hospital, Belgium

Conference

ECTRIMS 2022

Type

Peer-reviewed article

19 December 2022 19:06

ECTRIMS 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ECTRIMS 2022

15 November 2022 00:08

Study fails to show non-inferiority of rituximab with ocrelizumab

Presented By

Dr Izanne Roos, University of Melbourne, Australia

Conference

ECTRIMS 2022

Type

Peer-reviewed article

31 October 2022 11:16

EAN 2022

Letter from the Editor

Editor

Prof. Hans-Peter Hartung, Heinrich-Heine-University Düsseldorf, Germany

Conference

EAN 2022

22 August 2022 17:25

Tau autoimmunity associated with systemic disease

Presented By

Dr Andreia Magalhães, University of Zurich, Switzerland

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 17:15

Long-term effects of avalglucosidase alfa in late-onset Pompe disease

Presented By

Prof. Benedikt Schoser, Friedrich Baur Institute, Germany

Trial

Phase 3, COMET

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 17:12

European survey of patient satisfaction in the treatment of cancer-related neuropathic pain

Presented By

‪Prof. Martin Rakusa, ‬University Medical Centre Maribor, Slovenia

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 17:09

COVID-19 elevates risk of neurodegenerative disorders

Presented By

Dr Pardis Zarifkar, Rigshospitalet, Denmark

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 17:03

More headaches in adolescents during COVID-19 pandemic

Presented By

Dr Ayşe Nur Özdag Acarli, Ermenek State Hospital, Turkey

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:59

AstraZeneca vaccination and risk of cerebral venous sinus thrombosis

Presented By

Dr Jonathan Coutinho, Amsterdam University Medical Centre, the Netherlands

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:55

Large impact of COVID-19 on dementia diagnosis and care

Presented By

Prof. Bengt Winblad, Karolinska Institutet, Sweden

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:49

Seizure forecasting with non- and minimally-invasive devices

Presented By

Dr Pedro Faro Viana, King's College London, UK

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:44

Real-world efficacy of cenobamate in focal-onset seizures

Presented By

Dr Giovanni Falcicchio & Dr Ariadna Gifreu

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:38

Possible new biomarker for early neuronal death in mesial temporal lobe epilepsy

Presented By

Mr Ricardo Martins-Ferreira, University of Porto, Spain

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:33

Most acute stroke patients have undiagnosed risk factors

Presented By

Dr André Rêgo, Lausanne University Hospital and University of Lausanne, Switzerland

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:27

Absence of Susceptibility Vessel Sign points to malignancy in stroke patients

Presented By

Dr Morin Beyeler, Bern University Hospital, Switzerland

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:24

Acute stroke management: from time window to tissue window?

Presented By

Dr Davide Strambo, University of Lausanne, Switzerland

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:20

Intestinal alterations in patients with Parkinson’s disease

Presented By

Dr Gabriele Bellini, University of Pisa, Italy

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:12

Gene variants impact survival in monogenic Parkinson’s disease

Presented By

Dr Aymeric Lanore, Paris Brain Institute, France

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:08

When to start, switch, and stop MS therapy: Real-world evidence counts

Presented By

Prof. Melinda Magyari, Rigshospitalet, Denmark

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:36

Updated EAN-ECTRIMS guideline on pharmacological MS treatment

Presented By

Prof. Maria Pia Amato, University of Florence, Italy

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:31

Gut microbiota composition associated with disability worsening

Presented By

Dr Ayla Pauwels, Vrije Universiteit Brussel, Belgium

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:26

Teriflunomide in children with MS: final results of TERIKIDS

Presented By

Prof. Tanuja Chitnis, Brigham and Women’s Hospital, MA, USA

Trial

Phase 3, TERIKIDS

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:22

Estimating brain age in MS: machine learning versus deep learning

Presented By

Dr Lars Skattebøl, Oslo University Hospital, Norway

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:17

Ofatumumab improves cognitive processing speed

Presented By

Prof. Ralph H.B. Benedict, University at Buffalo, NY, USA

Trial

Phase 3, ASCLEPIOS I/II

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:13

Targeting cortical activation by transcranial magnetic stimulation

Presented By

Dr Anna Andreou, King's College London, United Kingdom

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:07

Erenumab more than doubles plasma CGRP levels

Presented By

Dr Nina Vashchenko, Sechenov First Moscow State Medical University, Russia

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:03

Over a third of patients responds late to CGRP antibodies

Presented By

Dr Cinzia Aurilia, University of Florence, Italy

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 14:59

Getting evidence into practice

Presented By

Prof. Carl Clarke & Prof. Barbara Tettenborn

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 14:50

EAN 2022 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

EAN 2022

14 July 2022 09:07

AAN 2022

Letter from the Editor

Editor

Prof. Hans-Peter Hartung, Heinrich-Heine-University Düsseldorf, Germany; Brain and Mind Center, University of Sydney, Australia; Medical University of Vienna, Austria; Palacky University Olomouc, Czech Republic

Conference

AAN 2022

2 June 2022 17:45

Cognitive, EEG, and MRI features in COVID-19 survivors

Presented By

Dr Giordano Cecchetti, Vita-Salute San Raffaele University, Italy

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 17:41

Interview with Prof. Natalia Rost

Expert

Prof. Natalia Rost, Massachusetts General Hospital / Harvard Medical School, USA

Conference

AAN 2022

2 June 2022 17:40

Neurological manifestations of COVID-19 worsen prognosis

Presented By

Dr Anna Cervantes-Arslanian, Boston University School of Medicine, MA, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 17:35

New evidence for biological basis of “COVID-19 brain fog”

Presented By

Dr Joanna Hellmuth, University of California, CA, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 17:26

Prasinezumab in Parkinson’s disease: delayed-start analysis of PASADENA trial

Presented By

Dr Gennaro Pagano, King’s College London, UK

Trial

Phase 2, PASADENA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 17:18

IPX203 versus immediate release carbidopa-levodopa

Presented By

Prof. Robert Hauser, USF Parkinson's Disease and Movement Disorders Center, FL, USA

Trial

Phase 3, RISE-PD

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 17:12

Impact of COVID-19 public health interventions

Presented By

Mr Ari Vandersluis, Heritage College of Osteopathic Medicine, OH, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 17:07

Intravenous thrombolysis after ischaemic stroke: When in doubt, leave it out?

Presented By

Dr Natalie LeCouffe, Amsterdam University Medical Centre, the Netherlands

Trial

Phase 3, MR CLEAN-NO IV

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 17:03

Better outcomes with mechanical thrombectomy in elderly stroke patients

Presented By

Dr Aisha Ali, University of Illinois, IL, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:59

Plasma NfL levels associated with cardiovascular risk

Presented By

Dr Hugo Aparicio, Boston University School of Medicine, MA, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:47

Non-invasive vagus nerve stimulation for acute stroke

Presented By

Prof. Ethem Murat Arsava, Hacettepe University, Turkey

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:42

Ravulizumab in patients with generalised myasthenia gravis

Presented By

Dr Tuan Hoang Vu, University of South Florida Physicians Group, FL, USA

Trial

Phase 3, CHAMPION MG

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:33

Gene therapy effective in older patients with spinal muscular atrophy

Presented By

Prof. Laurent Servais, MDUK Oxford Neuromuscular Centre, UK

Trial

RESTORE

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:27

Losmapimod for facioscapulohumeral muscular dystrophy

Presented By

Prof. Al-Rabi N. Tawil, University of Rochester, NY, USA

Trial

ReDUX4

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:22

SRP-9001 for treating patients with Duchenne muscular dystrophy

Presented By

Dr Jerry Mendell, Nationwide Children's Hospital, OH, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:17

Ublituximab versus teriflunomide in relapsing MS patients

Presented By

Prof. Lawrence Steinman, Stanford University, CA, USA

Trial

Phase 3, ULTIMATE I; ULTIMATE II

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:07

Ketogenic diet may improve disability and quality of life

Presented By

Dr James Nicholas Brenton, University of Virginia Medical Center, VA, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 15:53

Favourable additional safety data for ofatumumab

Presented By

Prof. Stephen Hauser, University of California, CA, USA

Trial

Phase 3, ALITHIOS

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 15:45

Predicting new T2 lesions using a machine learning algorithm

Presented By

Mr Bastien Caba, Biogen Digital Health, MA, USA

Trial

Phase 3, ADVANCE; ASCEND

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 15:38

Evobrutinib reduces volume of slowly expanding lesions

Presented By

Prof. Douglas Arnold, McGill University, Canada

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 15:34

Sustained long-term efficacy and safety of satralizumab in NMOSD

Presented By

Prof. Jeffrey Bennett, University of Colorado Hospital, CO, USA

Trial

Phase 3, SAkuraSky; SAkuraStar

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 15:29

Migraine may be an important obstetric risk factor

Presented By

Dr Alexandra Purdue-Smithe, Harvard Medical School, MA, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 14:57

Intranasal zavegepant safe and well tolerated in healthy adults

Presented By

Prof. Richard Bertz, University of Pittsburgh, PA, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 14:52

Telemedicine during COVID-19 pandemic highly appreciated

Presented By

Dr Chia-Chun Chiang, Mayo Clinic, MN, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 14:38

“Women with epilepsy should be encouraged to breastfeed”

Presented By

Prof. Kimford Meador, Stanford Comprehensive Epilepsy Center, CA, USA

Trial

MONEAD

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 13:52

Fenfluramine: possible new treatment for Lennox-Gastaut syndrome

Presented By

Dr Kelly Knupp, Children's Hospital Colorado, CO, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 13:42

Laser interstitial thermal therapy for refractory epilepsy

Presented By

Prof. Varun Kumar, Icahn School of Medicine at Mount Sinai, NY, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 13:17

Targeting senescent cells to treat age-related diseases

Presented By

Dr Miranda Orr, Wake Forest School of Medicine, NC, USA

Trial

Phase 2, StoMP-AD

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 12:29

Cardiorespiratory fitness protects against dementia

Presented By

Dr Edward Zamrini, Washington DC VA Medical Center, DC, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 12:12

Safety and effects of bosutinib in Lewy body dementia

Presented By

Dr Fernando Pagán, Georgetown University Hospital, DC, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 12:06

AAN 2022 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

AAN 2022

19 April 2022 22:42

ECTRIMS 2021

Introduction

Editor

Prof. Hans-Peter Hartung , Heinrich-Heine-University Düsseldorf, Germany

Conference

ECTRIMS 2021

15 December 2021 13:52

WNT9B-gene variant associated with doubled relapse risk in MS

Presented By

Ms Marijne Vandebergh, KU Leuven, Belgium

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:57

Melatonin associated with improved sleep quality in MS patients

Presented By

Dr Wan-Yu Hsu, University of California San Francisco, CA, USA

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:55

“Expanded Disability Status Scale 0 is not normal”

Presented By

Dr Stephen Krieger, Mount Sinai Hospital, NY, USA

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:51

Personality trait alterations in MS patients

Presented By

Dr Laura Chu, Memorial University of Newfoundland, Canada

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:49

Charcot Award 2021: Progressive MS, a personal perspective

Presented By

Prof. Alan J. Thompson, University College London, UK

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:48

Top score poster: Meta-analysis on the effect of DMTs

Presented By

Dr Mirko Capanna, University of Genoa, Italy

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:45

Cortical lesions predict disease progression and disability accumulation

Presented By

Dr Gian Marco Schiavi, University of Verona, Italy

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:40

Ocrelizumab shows long-term benefits in primary progressive MS

Presented By

Prof. Jerry S. Wolinsky, University of Texas Health Science Center at Houston, TX, USA

Trial

Phase 3, ORATORIO

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:39

Eculizumab, satralizumab, or inebilizumab for NMOSD?

Presented By

Prof. Dean Wingerchuk, Mayo Clinic Phoenix/Scottsdale, AZ, USA

Trial

Phase 3, N-MOmentum, PREVENT, SAkuraStar, SAkuraSky

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:37

Long-term efficacy of satralizumab for NMOSD

Presented By

Dr Ingo Kleiter, Ruhr-Universität Bochum, Germany

Trial

Phase 3, SAkuraStar, SAkuraSky

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:34

Long-term efficacy data: inebilizumab for NMOSD

Presented By

Prof. Bruce Cree, UCSF Multiple Sclerosis Center, CA, USA

Trial

Phase 3, N-MOmentum

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:31

Changes in GABA-receptor binding among cognitively impaired MS patients

Presented By

Prof. Hanneke Hulst, Amsterdam UMC, the Netherlands

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:28

T2 lesions independently predict early conversion to SPMS

Presented By

Dr Laura Lacruz-Ballester, Health Research Institute La Fe, Spain

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:26

Natural killer-like CD8+ T cells as a reservoir of clonal cells related to MS activity

Presented By

Dr Emilie Dugast, Centre de Recherche en Transplantation et Immunologie, France

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:23

The importance of MS progression independent of relapses

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:21

Early predictors of disability progression in paediatric-onset MS

Presented By

Dr Sifat Sharmin, University of Melbourne, Australia

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:15

High-sensitive biomarker detection in MS via novel ELISA assay

Presented By

Prof. Maria Cruz Sádaba, Private University San Pablo CEU, Spain

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:13

Cortical lesions predict cognitive impairment 20 years after MS diagnosis

Presented By

Mr Stefano Ziccardi, University of Verona, Italy

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:06

Applicability of sNfL measurement in clinical practice

Presented By

Prof. Elias Sotirchos, Johns Hopkins University, MD, USA

Trial

MS PATHS

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:04

MRI more sensitive for disease activity than relapses in SPMS

Presented By

Prof. Gavin Giovannoni, Queen Mary University of London, UK

Trial

Phase 3, EXPAND

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:58

ECTRIMS/EAN Clinical Guidelines on MS treatment: an update

Presented By

Prof. Xavier Montalban, Vall d’Hebron University Hospital, Spain

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:37

Rituximab most effective initial MS therapy in Swedish real-world study

Presented By

Mr Peter Alping, Karolinska Institutet, Sweden

Trial

Phase 4, COMBAT-MS

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:36

Ublituximab meets primary endpoint for relapsing MS

Presented By

Prof. Lawrence Steinman, Stanford University, CA, USA

Trial

Phase 3, ULTIMATE I, ULTIMATE II

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:33

Dynamic scoring system aids decision to switch MS therapies early

Presented By

Dr Camille Sabathé, French Institute of Health and Medical Research, France

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:31

Long-term suppression of MRI disease activity with ocrelizumab

Presented By

Dr Douglas Arnold, McGill University, Canada

Trial

Phase 3, OPERA I/II, ORATORIO

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:30

Stopping DMT: when or if at all?

Presented By

Prof. Ilya Kister (NYU Grossman School of Medicine, NY, USA); Prof. Gavin Giovannoni (Queen Mary University of London, UK)

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:25

The role of astrocyte phenotypes in acute MS lesions

Presented By

Dr Veit Rothhammer, University of Erlangen-Nürnberg, Germany

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:22

Promising results of intrathecal MSC-NTF cells in progressive MS

Presented By

Dr Jeffrey A. Cohen, Cleveland Clinic, OH, USA

Trial

Phase 2, BCT-101, SPRINT-MS

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:18

Preliminary data shows positive results of ATA188 for progressive MS

Presented By

Prof. Douglas Arnold, McGill University, Canada

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:16

Evobrutinib reduces relapses and MRI lesion activity

Presented By

Prof. Jens Kuhle (University Hospital Basel, Switzerland); Prof. Douglas Arnold (McGill University, Canada)

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:15

Primary endpoint of opicinumab for relapsing MS not met in AFFINITY trial

Presented By

Prof. Peter Calabresi, Johns Hopkins University, MD, USA

Trial

Phase 2, AFFINITY

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:12

Elezanumab did not outperform placebo in progressive and relapsing MS

Presented By

Prof. Bruce Cree, University of California, CA, USA

Trial

Phase 2, RADIUS-R, RADIUS-P

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:10

Ibudilast reduced retinal atrophy in primary progressive MS

Presented By

Dr Henrik Ehrhardt, Johns Hopkins University, MD, USA

Trial

Phase 2, SPRINT-MS

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:07

MS patients at risk of hampered immune response after vaccination

Presented By

Prof. Maria Pia Sormani, University of Genoa, Italy

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 10:49

Immunotherapy in MS does not influence COVID-19 severity and mortality

Presented By

Dr Gabriel Bsteh, Medical University of Vienna, Austria

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 10:45

Anti-CD20 antibodies associated with worse COVID-19 outcomes

Presented By

Dr Steve Simpson-Yap, University of Melbourne, Australia

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 10:41

ECTRIMS-EAN consensus on vaccination in MS patients

Presented By

Dr Mauricio Farez, Fundacion FLENI, Argentina

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 10:35

ECTRIMS 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Trial

COMBAT-MS, SAkuraSky, SAkuraStar, ULTIMATE I and II, ORATORIO

Conference

ECTRIMS 2021

1 November 2021 08:32

IHC 2021

Letter from the Editor

Editor

Prof. Hans-Peter Hartung, Heinrich-Heine-University Düsseldorf, Germany; Brain and Mind Center, University of Sydney, Australia; Medical University of Vienna, Austria; Palacky University Olomouc, Czech Republic

Conference

IHC 2021

8 November 2021 16:56

Occipital nerve stimulation effective and safe in chronic cluster headache

Presented By

Dr Poldi Wilbrink, Zuyderland Medical Centre, the Netherlands

Trial

Phase 3, ICON

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 16:30

Insights in drug-drug interactions facilitate rational polypharmacy

Presented By

Dr Victor Kaytser, Robert Wood Johnson Medical School, TX, USA

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 16:26

Rimegepant confers long-term improvements in MMDs

Presented By

Evan Popoff, Broadstreet Health Economics & Outcomes Research, Canada

Trial

Phase 2, BHV3000-201

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 16:19

First real-world effectiveness data of erenumab is promising

Presented By

Prof. Andreas R. Gantenbein, Zurzach Care, Switzerland

Trial

SQUARE

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 16:11

Galcanezumab effective in patients with episodic or chronic cluster headache

Presented By

Dr Charly Gaul, Headache Clinic Königstein, Germany

Trial

Phase 3

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 16:04

Central effects and affected somatosensory processing with galcanezumab in migraine

Presented By

Dr Hauke Basedau, Dr Kuan-Po Peng, University Medical Centre Hamburg-Eppendorf, Germany

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 16:00

Long-term safety and tolerability of atogepant in migraine

Presented By

Prof. Laszlo Mechtler, DENT Neurologic Institute, NY, USA

Trial

Phase 3, ADVANCE trial

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 15:53

Largest genome-wide association study of migraine to date

Presented By

Heidi M. Hautakangas, Institute for Molecular Medicine, Finland

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 15:39

Robust evidence that cluster headache has a genetic basis

Presented By

Dr Bendik S. Winsvold, Oslo University Hospital, Norway

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 15:35

Functional brainstem somatotopy of the trigeminal nerve during nociception

Presented By

Dr Lisa-Marie Sturm, University Clinic Hamburg Eppendorf, Germany

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 15:25

Morphological changes in cluster headache between attacks

Presented By

Dr Kuan-Lin Lai, Taipei Veterans General Hospital, Taiwan

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 15:21

Interictal pontine metabolism in migraine patients without aura

Presented By

Dr Samaira Younis, Danish Headache Centre, Denmark

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 14:55

AI-enabled ECG algorithm predicts atrial fibrillation risk in migraine

Presented By

Dr Nikita Chhabra, Mayo Clinic, NY, USA

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 14:45

Migraine may not be a risk factor for stroke

Presented By

Cevdet Acarsoy, Erasmus Medical Centre, the Netherlands

Trial

The Rotterdam study

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 14:38

Predictors of health-related quality of life in cluster headache

Presented By

Dr Soo-Kyoung Kim, Gyeongsang National University, South Korea

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 14:29

Dry eye disease is more prevalent in migraine

Presented By

Dr Bithi Chowdhury, Hindu Rao Hospital and MDMC Medical College, India

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 14:25

Voice change and throat swelling are cranial autonomic symptoms in primary headache

Presented By

Dr Nazia Karsan, King’s College London, UK

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 14:20

Association between physical inactivity and headache disorders

Presented By

Dr Arão Oliveira, University of São Paulo, Brazil

Trial

ELSA-Brasil cohort

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 14:13

Increased suicidal attempts and risks of ideation in medication-overuse headache

Presented By

Dr Yen-Feng Wang, Taipei Veterans General Hospital, Taiwan

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 14:08

Telemedicine beneficial for headache care during the pandemic

Presented By

Dr Chia-Chun Chiang , Mayo Clinic, NY, USA

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 13:58

Comparison of headaches after SARS-CoV-2 vaccination

Presented By

Dr Carl Göbel, Universitätsklinikum Schleswig-Holstein, Germany

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 13:55

Grey matter cortical changes in patients with persistent headache after COVID-19

Presented By

Dr Álvaro Planchuelo-Gómez, Universidad de Valladolid, Spain

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 13:43

Increased risk of cerebral venous thrombosis in COVID-19

Presented By

Dr Sajid Hameed , Aga Khan University, Pakistan

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 13:26

IHC 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

IHC 2021

30 September 2021 23:06

EAN 2021

Effect of prasinezumab on motor features in early PD

Trial

Phase 2, PASADENA

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 11:36

Levodopa-carbidopa intestinal gel in patients with advanced PD

Presented By

Dr József Szász, University of Târgu Mures, Romania

Trial

COSMOS

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 11:32

Safinamide improves non-motor symptoms in PD

Trial

SAFINONMOTOR

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 11:31

Exploring the possibilities

Presented By

Prof. Andres Lozano; Prof. Jean-François Aubry; Prof. Roland Beisteiner

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 11:20

Factors associated with decreased migraine attack risk

Presented By

Prof. Christian Wöber, Medical University of Vienna, Austria

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:59

Eptinezumab shows acute benefits during migraine attack

Trial

Phase 3, RELIEF

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:58

Erenumab superior to topiramate for migraine treatment

Trial

Phase 4, HER-MES

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:57

Pregnant migraine patients at higher risk of complications

Presented By

Dr Nirit Lev, Rabin Medical Center, Israel

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:53

Occipital nerve stimulation in drug-resistant cluster headache

Presented By

Dr Javier Membrilla, University Hospital La Paz, Spain

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:51

Rhythmicity in primary headache disorders

Presented By

Dr Christoph Schankin, University Hospital of Bern, Switzerland

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:50

Typing behaviour to remotely monitor clinical MS status

Presented By

Dr Ka-Hoo Lam, Amsterdam UMC, the Netherlands

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:37

Machine-learning method accurately classifies patients with MS

Type

Peer-reviewed article

18 August 2021 10:36

Positive results from ublituximab versus teriflunomide

Trial

Phase 3, ULTIMATE I, ULTIMATE II

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:35

Alemtuzumab in treatment-naïve patients with aggressive MS

Presented By

Dr Lucia Moiola, IRCCS San Raffaele Hospital, Italy

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:33

No higher early MS relapse frequency after stopping ponesimod

Presented By

Prof. Ludwig Kappos, University of Basel, Switzerland

Trial

Phase 3, OPTIMUM

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:32

Satralizumab efficacious in AQP4-IgG-positive patients with NMOSD

Trial

Phase 3, SAkuraSky, SAkuraStar

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:30

Good long-term safety and efficacy of inebilizumab in NMOSD

Presented By

Prof. Bruce Cree, University of California San Francisco, CA, USA

Trial

Phase 3, N-MOmentum

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:28

Severe outcomes of COVID-19 in patients with dementia

Presented By

Dr Agathe Vrillon, Hôpital Lariboisière Fernand-Widal, France

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:27

First evidence of brainstem involvement in COVID-19

Presented By

Dr Tommaso Bocci, University of Milan, Italy

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:20

Minimally invasive device to detect focal seizure activity

Presented By

Prof. Mark Cook, University of Melbourne, Australia

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:18

Long-term effectiveness of ANT-DBS in epilepsy confirmed

Trial

MORE

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:16

Hypertension pathology visible in white matter lesion volume

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:15

Intracerebral haemorrhage only slightly increases mortality in COVID-19 patients

Presented By

Dr Davide Sangalli, Alessandro Manzoni Hospital, Italy

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:15

Cognitive/behavioural alterations persistent after COVID-19

Presented By

Prof. Federica Agosta, Vita-Salute San Raffaele University, Italy

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:10

Stroke with covert brain infarction indicates high vascular risk

Presented By

Dr Thomas Meinel, Bern University Hospital, Switzerland

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:10

Good safety and efficacy of cenobamate for focal seizures

Trial

C013, C017, C021

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:10

Promising diagnostic accuracy of plasma GFAP

Presented By

Dr Tandis Parvizi, Medical University of Vienna, Austria

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:10

24-month pooled FIREFISH data of risdiplam in SMA

Trial

Phase 3, FIREFISH

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:07

Inability to recognise disgust as first cognitive symptom of ALS

Presented By

Ms Veronica Castelnovo, Vita-Salute San Raffaele University, Italy

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:06

Sex modulates effect of cognitive reserve on subjective cognitive decline

Presented By

Dr Giulia Giacomucci, University of Florence, Italy

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:05

Expanding precision medicine to stroke care

Presented By

Dr Svetlana Lorenzano, Sapienza University of Rome, Italy

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:05

Prenatal valproate exposure increases risk of adverse neurodevelopmental outcome

Trial

SCAN-AED

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:05

Pathogenic T-cell signature identified in myasthenia gravis

Presented By

Dr Bettina Schreiner, University of Zürich, Switzerland

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:04

Neural base of persistent hyposmia after COVID-19

Presented By

Dr Matteo Pardini, University of Genoa, Italy

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:00

Hypersensitivity to uncertainty in subjective cognitive decline

Presented By

Dr Bahaaeddin Attaallah, University of Oxford, United Kingdom

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:00

‘Mozart effect’ in epilepsy: why Mozart tops Haydn

Presented By

Prof. Ivan Rektor, Masaryk University, Czech Republic

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:00

Dexamethasone not indicated for chronic subdural haematoma

Presented By

Dr Ishita Miah, Leiden University Medical Center, the Netherlands

Trial

Phase 4, DECSA

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:00

Neurological symptoms and complications of COVID-19 affect outcomes

Presented By

Dr Nina Kleineberg, University Hospital Cologne, Germany

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 09:50

Letter from the Editor

Editor

Prof. Hans-Peter Hartung, Heinrich-Heine-University Düsseldorf, Germany

Conference

EAN 2021

17 August 2021 13:25

EAN 2021 Highlights Podcast

Presented By

Dr Michiel Tent

Conference

EAN 2021

9 July 2021 09:51

AAN 2021

Letter from the Editor

Editor

Prof. Hans-Peter Hartung, Heinrich-Heine-University Düsseldorf, Germany

Conference

AAN 2021

18 June 2021 10:46

Interview with AAN President Dr James C. Stevens

Expert

Dr James C. Stevens, MD, FAAN, Fort Wayne Neurological Center, Indiana, USA

Conference

AAN 2021

18 June 2021 09:58

Mast cell and neutrophil involvement in MS activity

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:52

Dysmetabolism may drive MS progression

Presented By

Dr Vijayshree Yadav, Oregon Health & Science University, USA

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:52

Serum NfL associated with clinical disability and brain atrophy

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:52

Plasma NfL and GFAP predict disability worsening in non-active secondary progressive MS

Trial

Phase 3, EXPAND

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:52

Serum NfL projects development of definite MS

Trial

Phase 3, REFLEX

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:52

Natalizumab versus fingolimod in subgroups of MS patients

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:51

Long-term safety of atogepant as migraine prophylaxis

Presented By

Prof. Messoud Ashina, University of Copenhagen, Denmark

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:51

Ublituximab versus teriflunomide in relapsing MS

Trial

Phase 2, ULTIMATE I, ULTIMATE II

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:50

Intranasal zavegepant effective treatment for acute migraine

Trial

Phase 3

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:50

The neurological impact of COVID-19

Presented By

Dr Anthony Fauci (National Institute of Allergy and Infectious Diseases, USA) & Dr Walter Koroshetz (National Institute of Neurological Disorders and Stroke, USA)

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:50

Tolebrutinib reduces brain lesions in very active MS

Trial

Phase 2

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:50

Ubrogepant for acute treatment of perimenstrual migraine

Trial

Phase 3

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:50

Chemosensory dysfunction often persistent after COVID-19

Presented By

Dr Nicolas Bussière, University of Quebec, Canada

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:50

Fenebrutinib at highest dose generally well tolerated

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:49

CGRP antagonists and complications in patients with Raynaud’s phenomenon

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:49

Obstructive sleep apnoea associated with lower cognition

Presented By

Dr David Colelli, University of Toronto, Canada

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:49

Pandemic results in decreased global stroke care

Presented By

Dr Thanh Nguyen, Boston University School of Medicine, MA, USA

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:49

Extraordinary transformation of epilepsy care in Ontario

Presented By

Dr O. Carter Snead III, University of Toronto, Canada

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:49

NfL is a better marker for neurodegeneration than T-tau

Presented By

Mr Jordan Marks, Mayo Clinic, MN, USA

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:49

Stroke uncommon in critically ill COVID-19 patients

Presented By

Dr Jonathon Fanning, University of Queensland, Australia

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:49

No neurodevelopmental effects of foetal antiseizure medication

Presented By

Dr Kimford Meador, Stanford University, CA, USA

Trial

MONEAD

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:44

Monoclonal antibody rapidly reduces brain amyloid

Presented By

Dr Chad Swanson, Neurology Business Group, Eisai Inc., NJ, USA

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:44

Neurologic symptoms in children with multisystem inflammatory syndrome

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:44

Durable seizure frequency reduction with cenobamate

Trial

Phase 3

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:43

Breast cancer treatment decreases risk of dementia

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:43

COVID-19 could cause novel seizures in patients without epilepsy

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:43

Predicting long-term prognosis in paediatric MS patients

Presented By

Dr Ermelinda De Meo, San Raffaele Hospital, Italy

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:42

Pimavanserin does not worsen motor function in patients with neurodegenerative disease

Trial

HARMONY, 019, 046, 032

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:42

MS therapies influence COVID-19 severity

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:42

Efficacy and safety of eptinezumab in acute migraine

Trial

Phase 3, RELIEF

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:41

Soticlestat in children with Dravet and Lennox-Gastaut

Trial

Phase 2, ELEKTRA

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:41

Functional and survival benefits of AMX0035 in ALS

Presented By

Dr Sabrina Paganoni, Massachusetts General Hospital, MA, USA

Trial

Phase 2, CENTAUR

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:39

Remission with rituximab in refractory generalised myasthenia gravis

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:39

Novel AAV-based gene therapy for Duchenne muscular dystrophy

Trial

Phase 2, SRP-9001-102

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:38

Stable long-term effects of deep brain stimulation in Parkinson’s disease

Trial

CSP468 VA/NINDS, INTREPID

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:36

Autoimmune mechanisms implicated in Parkinson’s disease

Presented By

Dr Camille Michaud, University of Montreal Hospital Research Centre, Canada

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:36

Novel non–D2-receptor-binding treatment for Parkinson’s disease psychosis

Presented By

Dr Stuart Isaacson, Parkinson's Disease and Movement Disorders Center of Boca Raton, FL, USA

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:35

Troriluzole for spinocerebellar ataxia

Presented By

Dr Melissa W. Beiner, Biohaven Pharmaceuticals, CT, USA

Trial

Phase 3, BHV4157-201

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:34

Lower-sodium oxybate for hypersomnia

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:34

Can linoleic acid help prevent stroke?

Presented By

Dr David Wu, University of Minnesota Medical School, MN, USA

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:34

No association between SSRIs and risk of ICH

Presented By

Dr Mithilesh Siddu, University of Miami, FL, USA

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:33

Gene therapy for Leber hereditary optic neuropathy

Trial

Phase 3, RESCUE, REVERSE

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:33

Patisiran for hATTR amyloidosis: 24-month efficacy and safety

Trial

APOLLO

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:32

Vutrisiran for hATTR amyloidosis with polyneuropathy

Presented By

Dr David Adams, Centre Hospitalier Universitaire Bicêtre, France

Trial

Phase 3, HELIOS-A

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:31

10 kHz spinal cord stimulation for painful diabetic neuropathy

Presented By

Prof. Erika Petersen, University of Arkansas, USA

Trial

SENZA-PDN

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:30

Effectiveness of public awareness campaigns on stroke signs

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:25

Blood pressure reduction after LVO potential target for intervention

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:23

AAN 2021 Highlights Podcast

Presented By

Michiel Tent, Medicom

Conference

AAN 2021

6 May 2021 13:37

MS disease-modifying therapies influence COVID-19 infection severity

Presented By

Dr Maria Pia Sormani, University of Genoa, Italy

Conference

AAN 2021

22 April 2021 10:35

Duration and severity of chemosensory dysfunction following COVID-19 infection

Presented By

Nicholas Bussière, University of Quebec, Canada

Conference

AAN 2021

22 April 2021 10:35

The role of brain ATP abnormalities in MS disease progression

Presented By

Dr Vijayshree Yadav, Oregon Health & Science University, USA

Conference

AAN 2021

22 April 2021 10:35

COVID-19 pandemic results in decreased global stroke care

Presented By

Dr Thanh Nguyen, Boston University School of Medicine, Massachusetts, USA

Conference

AAN 2021

22 April 2021 10:35

Long-term survival outcomes of AMX0035 for ALS

Presented By

Dr Sabrina Paganoni, Massachusetts General Hospital, USA

Trial

Phase 2, CENTAUR

Conference

AAN 2021

22 April 2021 10:35

Long-term follow-up outcomes of deep brain stimulation in Parkinson disease

Presented By

Dr Jill Ostrem (University of California, USA) & Dr Jerrold Vitek (University of Minnesota, USA)

Conference

AAN 2021

20 April 2021 10:37

Neurological symptoms in children with inflammatory syndrome following COVID-19

Presented By

Dr Omar Abdel-Mannan, University College London, UK

Conference

AAN 2021

20 April 2021 10:37

Mast cell and neutrophil involvement in the disease activity of MS

Presented By

Dr Antonino Giordano, San Raffaele Scientific Institute, Milan, Italy

Conference

AAN 2021

20 April 2021 10:37

Neurofilament light outperforms total tau as biomarker for neurodegeneration

Presented By

Dr Jordan Marks, Mayo Clinic, Minnesota, USA

Conference

AAN 2021

20 April 2021 10:37

Obstructive sleep apnoea common in cognitively impaired population

Presented By

David Colelli, University of Toronto, Canada

Conference

AAN 2021

20 April 2021 10:37

No effect of foetal antiseizure exposure on neurodevelopmental outcomes at age 3

Presented By

Prof. Kimford J. Meador, Stanford University, California, USA

Trial

MONEAD

Conference

AAN 2021

19 April 2021 10:50

sNfL projects development of definite MS

Presented By

Prof. Jens Kuhle, University of Basel, Switzerland

Trial

Phase 3, REFLEX

Conference

AAN 2021

19 April 2021 10:50

No link between antidepressants and intracerebral haemorrhage in stroke patients

Presented By

Dr Mithilesh Siddu, George Washington University, Washington DC, USA

Conference

AAN 2021

19 April 2021 10:50

Long-term safety of atogepant as preventive treatment of migraine

Presented By

Prof. Messoud Ashina, University of Copenhagen, Denmark

Conference

AAN 2021

19 April 2021 10:49

Cenobamate long-term efficacy and concentration reference range

Presented By

Dr Michael R. Sperling, Thomas Jefferson University, Pennsylvania, USA

Trial

YKP3089C013, YKP3089C017, YKP3089C021

Conference

AAN 2021

19 April 2021 10:49